Tract Closure in PCNL
Study Phase: N/A
Recruitment Status: Recruiting
Start Date: July 01, 2026
End Date: June 01, 2028
This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic assessment. The researchers hypothesize that adjunctive hemostatic agent use reduces perioperative hemoglobin decline compared with balloon tamponade alone and improves tract-related hemostasis outcomes.
Inclusion criteria:
- At least one stone ≥ 1.2cm
- Scheduled to undergo planned PCNL
- Age ≥ 18 years
Exclusion criteria:
- Unable to provide informed consent
- Pre-existing nephrostomy tube
- Multi access cases
- Stone in calyceal diverticulum/hydrocalyx
- Preoperatively planned overnight admission for any reason
- Infundibular stenosis
- Coagulation disorders
- Other significant anatomic abnormalities
-
Conditions:
- Nephrolithiasis